{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:18:44Z","timestamp":1788959924960,"version":"build-2803163510"},"reference-count":62,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"Importance<\/jats:title>Erythrodermic atopic dermatitis (AD) is a severe AD subtype defined by extensive skin involvement, leading to complications and sometimes hospitalization.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess dupilumab\u2019s efficacy and safety in patients with erythrodermic AD in clinical trials.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This post hoc analysis included patients enrolled in 6 multicenter, multinational, randomized, double-blind, placebo-controlled trials. Patients included in this analysis met erythrodermic AD criteria of 90% or greater body surface area (BSA) affected by AD and Global Individual Sign Score for erythema of 1 or higher. Data analyses for this post hoc analysis were conducted between March 5, 2019, and October 24, 2020.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Dupilumab once weekly or every 2 weeks, or placebo, either as monotherapy or with concomitant topical corticosteroids (TCS).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Efficacy (BSA, Eczema Area and Severity Index [EASI] score, Peak Pruritus Numerical Rating Scale [PP-NRS] score), changes in serum biomarkers (thymus and activation-regulated chemokine, total immunoglobulin E, lactate dehydrogenase), and safety (incidence of adverse events) at week 16. Data were pooled within each regimen; monotherapy and concomitant TCS results are shown separately.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 3075 randomized patients, 209 met criteria for erythrodermic AD at baseline, with the median age being 31 and 39 years in the monotherapy and concomitant TCS trials, respectively, similar to the overall populations (34 and 36 years, respectively); 71.3% (n\u2009=\u200997) and 74.0% (n\u2009=\u200954) of patients, respectively, were male (compared with 58.7% and 60.6% in the overall populations). In patients with erythrodermic AD, dupilumab once weekly and every 2 weeks vs placebo significantly improved percentage of BSA affected by AD (least squares mean percent change [SE]) with monotherapy (\u221242.0% [7.7%] and \u221239.9% [6.5%] vs \u221217.2% [11.0%]; P<\/jats:italic>\u2009=\u2009.03) and concomitant TCS (\u221263.2% [6.7%] and \u221256.1% [9.1%] vs \u221214.5% [7.3%]; P<\/jats:italic>\u2009&amp;lt;\u2009.001); EASI score with monotherapy (\u221258.5% [9.0%] and \u221258.3% [7.9%] vs \u221222.3% [12.4%]; P<\/jats:italic>\u2009=\u2009.004 and P<\/jats:italic>\u2009=\u2009.003, respectively) and concomitant TCS (\u221278.9% [7.8%] and \u221270.6% [10.1%] vs 19.3% [8.2%]; P<\/jats:italic>\u2009&amp;lt;\u2009.001); and PP-NRS score in monotherapy (\u221245.9% [7.8%] and \u221233.9% [6.6%] vs \u22120.6% [9.4%]; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and concomitant therapy (\u221253.0% [8.1%] and \u221255.7% [10.8%] vs \u221226.0% [8.8%]; P<\/jats:italic>\u2009=\u2009.006 and P<\/jats:italic>\u2009=\u2009.01, respectively). Nominally statistically significant improvement was seen as early as week 1 (EASI and PP-NRS scores with monotherapy). Biomarker levels were significantly reduced vs placebo. The most frequent adverse events in dupilumab-treated patients were injection-site reaction, conjunctivitis, and nasopharyngitis.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this post hoc analysis of 6 randomized clinical trials, treatment with dupilumab resulted in rapid, sustained improvements in AD signs and symptoms with acceptable safety in patients with erythrodermic AD, similar to those in the trials\u2019 overall patient population.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifiers: NCT01859988<\/jats:ext-link>, NCT02277743<\/jats:ext-link>, NCT02277769<\/jats:ext-link>, NCT03054428<\/jats:ext-link>, NCT02260986<\/jats:ext-link>, NCT02755649<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2022.6192","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T16:29:42Z","timestamp":1675268982000},"page":"255","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis"],"prefix":"10.1001","volume":"159","author":[{"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"The George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Cork","sequence":"additional","affiliation":[{"name":"Sheffield Dermatology Research, University of Sheffield, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Medical Center, New York, New York"},{"name":"Rockefeller University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lockshin","sequence":"additional","affiliation":[{"name":"US Dermatology Partners, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Irvine","sequence":"additional","affiliation":[{"name":"School of Medicine, Trinity College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Bum","family":"Kim","sequence":"additional","affiliation":[{"name":"Pusan National University Hospital, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Lu","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bansal","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Rossi","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsalan","family":"Shabbir","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"doi220070r1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1046\/j.1365-4362.1998.00228.x","article-title":"Erythroderma: a clinico-etiologic study of 90 cases.","volume":"37","author":"Pal","year":"1998","journal-title":"Int J Dermatol"},{"issue":"1","key":"doi220070r2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/ijd.2004.43.issue-1","article-title":"Erythroderma\/exfoliative dermatitis: a synopsis.","volume":"43","author":"Sehgal","year":"2004","journal-title":"Int J Dermatol"},{"issue":"2","key":"doi220070r3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.clindermatol.2004.06.018","article-title":"Life-threatening erythroderma: diagnosing and treating the \u201cred man\u201d.","volume":"23","author":"Rothe","year":"2005","journal-title":"Clin Dermatol"},{"issue":"5","key":"doi220070r4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/01.ASW.0000463573.40637.73","article-title":"A review of the diagnosis and management of erythroderma (generalized red skin).","volume":"28","author":"Mistry","year":"2015","journal-title":"Adv Skin Wound Care"},{"issue":"6","key":"doi220070r6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ced.v46.6","article-title":"Erythroderma (exfoliative dermatitis): part 1: underlying causes, clinical presentation and pathogenesis.","volume":"46","author":"Tso","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"doi220070r7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1067\/mjd.2001.116224","article-title":"The incidence of erythroderma: a survey among all dermatologists in the Netherlands.","volume":"45","author":"Sigurdsson","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi220070r8","doi-asserted-by":"publisher","first-page":"9774","DOI":"10.1038\/s41598-020-66040-7","article-title":"Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center.","volume":"10","author":"Miyashiro","year":"2020","journal-title":"Sci Rep"},{"issue":"7","key":"doi220070r9","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/jdv.2010.24.issue-7","article-title":"Acquired erythroderma in adults: a clinical and prognostic study.","volume":"24","author":"Khaled","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi220070r10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000342365","article-title":"Erythroderma: a clinical and prognostic study.","volume":"225","author":"Li","year":"2012","journal-title":"Dermatology"},{"issue":"1","key":"doi220070r11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3315\/jdcr.2016.1222","article-title":"Erythroderma: a clinical and etiological study of 103 patients.","volume":"10","author":"C\u00e9sar","year":"2016","journal-title":"J Dermatol Case Rep"},{"issue":"12","key":"doi220070r12","doi-asserted-by":"publisher","first-page":"e616","DOI":"10.1111\/ijd.13322","article-title":"Dermoscopy as an auxiliary tool in the differentiation of the main types of erythroderma due to dermatological disorders.","volume":"55","author":"Errichetti","year":"2016","journal-title":"Int J Dermatol"},{"issue":"4","key":"doi220070r13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s13555-016-0141-6","article-title":"Dermoscopy in general dermatology: a practical overview.","volume":"6","author":"Errichetti","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"doi220070r14","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.3390\/jcm9092684","article-title":"Efficacy of dupilumab on different phenotypes of atopic dermatitis: one-year experience of 221 patients.","volume":"9","author":"Tavecchio","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"doi220070r15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0190-9622(96)90496-X","article-title":"Erythroderma: a clinical and follow-up study of 102 patients, with special emphasis on survival.","volume":"35","author":"Sigurdsson","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"doi220070r16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-5945-5-5","article-title":"Erythroderma: a clinical study of 97 cases.","volume":"5","author":"Akhyani","year":"2005","journal-title":"BMC Dermatol"},{"issue":"2","key":"doi220070r19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/bjd.2007.156.issue-2","article-title":"A systematic review of the safety of topical therapies for atopic dermatitis.","volume":"156","author":"Callen","year":"2007","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi220070r20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/jde.2004.31.issue-4","article-title":"Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis.","volume":"31","author":"Furue","year":"2004","journal-title":"J Dermatol"},{"issue":"1","key":"doi220070r21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1046\/j.1365-2133.2003.04934.x","article-title":"Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis.","volume":"148","author":"Furue","year":"2003","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi220070r22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jaad.2010.01.035","article-title":"Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts.","volume":"64","author":"Haeck","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi220070r23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","article-title":"JAK inhibitors for atopic dermatitis: an update.","volume":"20","author":"He","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"doi220070r24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1172\/JCI21060","article-title":"New insights into atopic dermatitis.","volume":"113","author":"Leung","year":"2004","journal-title":"J Clin Invest"},{"issue":"1","key":"doi220070r25","doi-asserted-by":"publisher","first-page":"8707","DOI":"10.1038\/s41598-017-09207-z","article-title":"The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins.","volume":"7","author":"Brunner","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"doi220070r26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaad.2017.09.074","article-title":"A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis.","volume":"78","author":"Yu","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"doi220070r27","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1016\/j.jaip.2020.07.015","article-title":"Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures.","volume":"8","author":"Glickman","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"doi220070r28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents.","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi220070r29","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.2018.178.issue-5","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9).","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi220070r30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/bjd.2019.180.issue-4","article-title":"TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries.","volume":"180","author":"Gerbens","year":"2019","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi220070r31","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/bjd.v183.6","article-title":"The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema.","volume":"183","author":"Vermeulen","year":"2020","journal-title":"Br J Dermatol"},{"issue":"7","key":"doi220070r32","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3848","article-title":"Dupilumab provides significant clinical benefit in a phase 3 trial in adolescents with uncontrolled atopic dermatitis irrespective of prior systemic immunosuppressant use.","volume":"101","author":"Deleuran","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"doi220070r33","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s13555-021-00558-0","article-title":"Dupilumab in adults with moderate-to-severe atopic dermatitis and prior use of systemic non-steroidal immunosuppressants: analysis of four phase 3 trials.","volume":"11","author":"Griffiths","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"doi220070r34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review.","volume":"133","author":"Roekevisch","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"doi220070r35","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes.","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"doi220070r36","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice.","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"doi220070r37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease.","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"doi220070r38","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases.","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"doi220070r39","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.v75.5","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ra antibody, is required to broadly inhibit type 2 inflammation.","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"issue":"6","key":"doi220070r40","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"10013","key":"doi220070r41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"issue":"24","key":"doi220070r42","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"doi220070r43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"doi220070r44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial.","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"10086","key":"doi220070r45","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"doi220070r46","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis.","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"doi220070r47","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/bjd.v182.5","article-title":"Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).","volume":"182","author":"Wollenberg","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi220070r48","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1080\/09546634.2020.1871463","article-title":"Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study.","volume":"33","author":"Beck","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"doi220070r49","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40272-021-00459-x","article-title":"Laboratory safety of dupilumab in patients aged 6-11 years with severe atopic dermatitis: results from a phase III clinical trial.","volume":"23","author":"Paller","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"2","key":"doi220070r50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40257-020-00583-3","article-title":"Effect of dupilumab on laboratory parameters in adolescents with atopic dermatitis: results from a randomized, placebo-controlled, phase 3 clinical trial.","volume":"22","author":"Siegfried","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"doi220070r51","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease.","volume":"137","author":"Ungar","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi220070r52","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis\u2014a review on behalf of the International Eczema Council.","volume":"147","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"4S","key":"doi220070r53","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"doi220070r54","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"doi220070r55","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3389\/fimmu.2020.01768","article-title":"Tape-strip proteomic profiling of atopic dermatitis on dupilumab identifies minimally invasive biomarkers.","volume":"11","author":"He","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"doi220070r56","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","article-title":"Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis.","volume":"77","author":"Thyssen","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi220070r57","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.v181.3","article-title":"Conjunctivitis in dupilumab clinical trials.","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi220070r58","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","article-title":"Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients.","volume":"83","author":"Espinosa","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"doi220070r59","doi-asserted-by":"publisher","first-page":"818","DOI":"10.2340\/00015555-3208","article-title":"Diagnosis of mycosis fungoides following administration of dupilumab for misdiagnosed atopic dermatitis.","volume":"99","author":"Chiba","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"10348","key":"doi220070r60","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"doi220070r61","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis.","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"doi220070r62","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial.","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"doi220070r5","doi-asserted-by":"crossref","DOI":"10.1002\/9781118441213","volume-title":"Rook\u2019s Textbook of Dermatology","author":"Griffiths","year":"2016","edition":"9th ed"},{"key":"doi220070r17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-3-319-75623-3_19","volume-title":"Life-Threatening Rashes","author":"Harper-Kirksey","year":"2018"},{"key":"doi220070r18","volume-title":"StatPearls","author":"Austad","year":"2021"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2800880\/jamadermatology_paller_2023_oi_220070_1677862986.71518.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T15:13:37Z","timestamp":1678893217000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2800880"}},"subtitle":["A Post Hoc Analysis of 6 Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.6192","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}